SGLT2 Inhibitors in Heart Failure: 2025 PLAB 2 Research Update

Introduction

For PLAB 2 candidates, staying updated with the latest cardiovascular research is crucial for both exam success and clinical practice. Sodium-glucose co-transporter 2 (SGLT2) inhibitors have emerged as game-changers in heart failure management, with significant research developments in 2024-2025 that are essential to understand for your PLAB 2 examination.

Mechanism of Action

SGLT2 inhibitors originally developed for type 2 diabetes have demonstrated remarkable cardiovascular benefits through multiple mechanisms:

• Cardiorenal effects: Reduced preload and afterload through osmotic diuresis

• Improved myocardial energetics: Enhanced ketone body utilization

• Reduced epicardial fat: Anti-inflammatory effects

• Natriuresis: Decreased sodium reabsorption

2024-2025 Key Research Updates

1. EMPEROR-Preserved and EMPEROR-Reduced Trials Long-Term Follow-up

New 5-year follow-up data has confirmed sustained benefits of empagliflozin in both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF), establishing SGLT2 inhibitors as foundational therapy.

2. Earlier Initiation in Acute Heart Failure

Recent studies support initiating SGLT2 inhibitors during hospitalization for acute decompensated heart failure, showing:

• Reduced readmission rates

• Improved functional capacity at 30 days

• No significant increase in adverse events

3. Combination Therapy Insights

Research has clarified optimal combination strategies:

• SGLT2 inhibitors + ARNIs (sacubitril/valsartan)

• Triple therapy with beta-blockers and MRAs

• Sequential initiation rather than simultaneous

PLAB 2 Clinical Implications

History Taking Points

When taking history for a heart failure patient in PLAB 2:

• Medication review: Ask about diabetic medications (SGLT2 inhibitors)

• Symptom tracking: Dyspnea improvement, exercise tolerance

• Side effects: Genital candiduria, polyuria

Examination Findings

• Assess for fluid overload resolution

• Monitor blood pressure (SGLT2 inhibitors can cause hypotension)

• Check for signs of euvolemia

Management Discussion

For PLAB 2, be prepared to counsel patients on:

1. Benefits: "SGLT2 inhibitors like empagliflozin have been shown to reduce heart failure hospitalizations and improve survival"

2. Side effects: "You may notice increased urination and potential genital infections"

3. Monitoring: "We'll need to check your kidney function and blood pressure regularly"

Updated Guidelines Summary

Clinical Scenarios for PLAB 2

Scenario 1: New Diagnosis of HFrEF

A 65-year-old presents with dyspnea. Echo shows LVEF 35%. Management should include:

• Start ACEi/ARB

• Add beta-blocker

• Add SGLT2 inhibitor

• Consider MRAs

Scenario 2: Hospitalized Acute HF

Consider initiating SGLT2 inhibitor before discharge if:

• Blood pressure adequate (SBP > 100 mmHg)

• No significant renal impairment

• No severe hyperkalemia

Key Takeaways for PLAB 2

1. SGLT2 inhibitors are now first-line in all heart failure types

2. Dual cardiorenal benefits make them unique

3. Generally well-tolerated with manageable side effects

4. Earlier initiation is now recommended

5. Combination therapy provides additive benefits

Conclusion

SGLT2 inhibitors represent one of the most significant therapeutic advances in cardiovascular medicine. For PLAB 2, ensure you understand their role in heart failure management, can counsel patients appropriately, and recognize the latest evidence supporting their use across all heart failure phenotypes.

Related Topics to Review:

• Heart failure classification (HFrEF vs HFpEF vs HFmrEF)

• Diuretic management in acute heart failure

• ARNIs and their place in therapy

• Renal considerations with SGLT2 inhibitors